ResMed (RMD) director sells 2,055 shares at $255 in Form 4

ResMed Inc. (RMD) director files Form 4 for planned stock sale.

Rhea-AI Filing Summary

ResMed Inc. (RMD) director files Form 4 for planned stock sale. Director Jan De Witte reported selling 2,055 shares of ResMed common stock on 11/25/2025 at a price of $255 per share. After this transaction, De Witte beneficially owns 4,261 shares, held directly.

The sale was coded as an "S" transaction and was carried out under a Rule 10b5-1 trading plan adopted on August 18, 2025, indicating it was pre-arranged under preset instructions rather than a discretionary, one-off trade.

Insider Trade Summary

Net Seller: 2,055 shares

Net Sell 1 txn

Insider De Witte Jan

Role Director

Sold 2,055 shs ($524K)

Type	Security	Shares	Price	Value
Sale	ReMed Common Stock	2,055	$255.00	$524K

Holdings After Transaction: ReMed Common Stock — 4,261 shares (Direct)

Footnotes (1)

1. F1. The transaction was conducted under a Rule 10b5-1 plan adopted on August 18, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ResMed Inc. (RMD) report in this Form 4?

ResMed Inc. reported that director Jan De Witte sold 2,055 shares of ResMed common stock on 11/25/2025 at a price of $255 per share.

How many ResMed (RMD) shares does the director own after the reported sale?

After the transaction, director Jan De Witte beneficially owns 4,261 shares of ResMed common stock, held in direct ownership form.

Was the ResMed (RMD) insider trade executed under a Rule 10b5-1 plan?

Yes. The filing explains that the sale was conducted under a Rule 10b5-1 trading plan that was adopted on August 18, 2025.

What is the role of the reporting person at ResMed Inc. (RMD)?

The reporting person, Jan De Witte, is identified as a director of ResMed Inc. in the filing.

What transaction code is used for the ResMed (RMD) insider sale?

The Form 4 uses transaction code "S", which indicates an open market or private sale of non-derivative securities.

Does this ResMed (RMD) Form 4 involve any derivative securities?

No derivative securities are reported as acquired, disposed of, or beneficially owned in Table II of this Form 4 excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/26/2025 - 02:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

De Witte Jan

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD.

C/O RESMED INC

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ReMed Common Stock	11/25/2025		S(1)		2,055	D	$255	4,261	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted on August 18, 2025.

	Jan De Witte, director	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.